Cellectis (CLLS) Change in Accured Expenses (2021 - 2022)
Cellectis (CLLS) posted quarterly Change in Accured Expenses of $37000.0 for Q1 2022, down 77.84% year-over-year from $167000.0 in Q1 2021, and down 77.84% quarter-over-quarter from $167000.0 in Q1 2021.
Powered by 
Analysis
Cellectis (CLLS) Change in Accured Expenses (2021 - 2022) Analysis & Trends
Cellectis' Change in Accured Expenses history runs 2 years deep, the most recent figure standing at $37000.0 for Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | - |